Table 1B. Clinical characteristics for Eurasian and Australian patients.
| Timing for characteristics | Clinical characteristics and treatments | Eurasian patients (n = 30) | Australian patients (n = 15) |
|---|---|---|---|
| Findings at diagnosis | Age | 61 (56.5–65) | 63 (57–74) |
| Gleason score 6 | 1 | 0 | |
| Gleason score 7 | 14 | 3 | |
| Gleason score 8 | 6 | 4 | |
| Gleason score 9 | 3 | 4 | |
| Initial treatment | RP | 22 | 7 |
| RP and pelvic lymph node dissection | 13 | 0 | |
| Radiotherapy | 8 | 5 | |
| Adjuvant treatment | Radiotherapy | 4 | 5 |
| ADT | 10 | 0 | |
| Number of salvage treatments before LuPSMA (median, range) | 3 (1–4) | 1 (1–2) | |
| Radiotherapy | 10 | 0 | |
| Lymph node dissection | 3 | 0 | |
| ADT | 14 | 0 | |
| Docetaxel | 10 | 2 | |
| Abiraterone | 10 | 0 | |
| Enzalutamide | 3 | 0 | |
| Findings at start of LuPRLT | Age (y, median, IQR) | 69 (64–73) | 73 (63–77) |
| PSA (µg/l median, IQR) | 23.5 (4–44) | 11 (1.5–41) |
Abbreviations as in Table 1A.